Authors
Latest:
Legal: Foreign PolicyCompliance requires overcoming cultural barriers. To start with, in some countries the taboo against bribery is not as strong as it is here.
Latest:
Track and TraceThe issue of pedigree requirements is emerging at the state level-and figuring out to what extent that will push back to the manufacturers.
Latest:
Pressed Into Action: Measuring Pharma’s Reputation ReversalStudy analyzes mainstream media coverage of the industry before and after the COVID-19 lockdown.
Latest:
Vaccines: Market on the ReboundMergers have cut the field of companies with real marketing and manufacturing muscle from 25 to five. The 2004 vaccine market will double by 2009.
Latest:
Agency Best Practice in Regulatory ComplianceNO ONE REALLY KNOWS WHAT A DOCTOR IS thinking most of the time, and those of us who are patients can be happy about that. We are comforted when physicians keep their counsel until they complete an examination.
Latest:
Pfizer on the Line for Warner-Lambert's Past ProblemsA former Warner-Lambert employee has blown the whistle on the company's "shadowing program," alleging that some physicians accepted money in exchange for allowing pharma sales representatives to meet with patients, review charts, and recommend prescriptions. According to the lawsuit, Warner-Lambert-since acquired by Pfizer-tried to boost sales of its epilepsy drug Neurontin (gabapentin) by tracking prescriptions and rewarding high-prescribing physicians with gifts such as cash, trips to resorts, and lucrative speaking and consulting jobs-as well as paying them to enter patients in clinical trials. The program allegedly paid 75-100 US doctors at least $350 per day to let sales reps watch
Latest:
Sewing Up New SalesMore than high-call frequency will be necessary to succeed in an increasingly competitive sales environment.
Latest:
Who Pays for Specialty Medicines?Providers and patients fish for that delicate balance between access and abandonment.
Latest:
The Ins and Outs of EAPsFor a patient who is running out of hope, waiting for a drug to be approved can be interminable. Even on the fast track, a review can take six months or longer. Some patients with life-threatening diseases cannot afford to wait. In response, many countries have developed expanded access programs (EAPs) that give patients with no other viable alternative access to medically important drugs before they are commercialized.
Latest:
Physician FrustrationAs the industry thinks about new sales force models, it should look beyond ROI numbers, toward a new paradigm that not only works for pharma, but also for its customers.
Latest:
The Road to Nowhere?Drug companies can do to specialists what Intel did to PC box makers: commoditize them.
Latest:
The Road to Nowhere?Drug companies can do to specialists what Intel did to PC box makers: commoditize them.
Latest:
Physician FrustrationAs the industry thinks about new sales force models, it should look beyond ROI numbers, toward a new paradigm that not only works for pharma, but also for its customers.
Latest:
Best Bang for the BuckKnowing what falls into fixed and variable expenses will make it easier to note what falls into high priority.
Latest:
EGA Calls for Removal of Barriers to Generics in EuropeAdrian van den Hoven, Director General of the European Generics Association (EGA), this week called for the removal of barriers to generic medicines across the European Union.
Latest:
Ignorance is No ExcuseState clinical trials requirements are in place to protect people from being exploited, or unsafely exposed to compounds. Forty years later, it's easy to say, "How did this happen?"
Latest:
More Than a Game of Keep AwayIndustry self-policing may be the only way to stop state Legislators who want to ban sales Reps, and even whole companies, from using Prescribing information.
Latest:
Legal: The Kickback EffectCriminal penalties for violating the Foreign Corrupt Practices Act can be substantial. Businesses found guilty may be fined upwards of $2.5 million for each offense, or twice the amount gained as a result of the violation.
Latest:
Sewing Up New SalesMore than high-call frequency will be necessary to succeed in an increasingly competitive sales environment.
Latest:
Measuring the Value of KOL InteractionsThought leaders are a critical component of a pharmaceutical company?s professional marketing and medical strategies. But companies face a real challenge in creating, maintaining, and leveraging those relationships while safely navigating logistical issues and regulatory waters.
Latest:
Out to Lunch?It's twelve o'clock-do you know where your reps are? According to research from Health Strategies Group, lunches provide one of the few opportunities in today's short-call environment for sit-down discussions with doctors. The average length of a lunch is 13 minutes, with an average of three physicians per meeting.
Latest:
Opinion: Memo to von EschenbachOften, post-approval marketing studies don't materialize because drug companies question their value. Independent review of the need for such studies would address pharma's concern that they may be warranted.
Latest:
Knowledge-Based Outsourcing: Driving Deeper InsightsTracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why.
Latest:
The Place of Digital in the Pharma Marketing MixThirty-nine years ago this past June, an article appeared in BusinessWeek that offered readers what was for its time a startling degree of foresight.
Latest:
50 5 2005Implementation of policies that respond to industry compliance standards poses a considerable burden for companies in terms of time and expense. Unless industry changes its response to state laws, the condition will worsen.
Latest:
One Pill Makes You SmallThe obesity pipeline, despite a hugely underserved market potentially worth $11 billion, is awfully thin.
